Tag Archives: TGTX

Top 10 Warren Buffett Stocks For 2019

Warren Buffett has plenty on the line if the United States and China can’t settle their trade differences. But the Oracle of Omaha isn’t that concerned about the relationship.

“We’ve done remarkably well with trade in China,” Buffett said of the US at Berkshire Hathaway’s annual shareholders meeting Saturday in Omaha, Nebraska. “We will have disagreements with each other. We’ll have disagreements with other countries on trade. But it’s just too big, and too obvious that the benefits are huge and the world’s dependent on, in a major way for its progress.”

Threats of a trade war between the world’s biggest economies have loomed for months, and both countries have threatened to slap steep tariffs on tens of billions of dollars of exports.

The tensions have rattled global markets — so far this year, for example, the S&P 500 (DVS) index has swung wildly.

Buffett has several interests in China. His conglomerate Berkshire has a massive stake in the Chinese car company BYD, as well as big holdings of Apple (AAPL), GM (GM) and Coca-Cola (KO). All of them have a major presence in the Asian nation.

Top 10 Warren Buffett Stocks For 2019: Ballard Power Systems, Inc.(BLDP)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wednesday carried the stock market further into record territory, as investors celebrated favorable readings on U.S. gross domestic product, which rose an estimated 4.2% during the second quarter. The Nasdaq Composite led the way higher with gains of 1%, but a solid advance for the S&P 500 pointed to the broad-based nature of the late summer rally. Adding to the positive sentiment among investors was good news from several prominent companies. Square (NYSE:SQ), Glaukos (NYSE:GKOS), and Ballard Power Systems (NASDAQ:BLDP) were among the best performers on the day. Here’s why they did so well.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Ballard Power Systems (BLDP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Scott Levine]

    Shares of Ballard Power Systems (NASDAQ:BLDP), a global leader in fuel cell solutions, climbed 16% in August, according to data from S&P Global Market Intelligence. In addition to the late-August announcement of a major deal with Weichai Power, a leading automotive manufacturer located in China, shareholders celebrated the news that Zhongshan Broad-Ocean Motor Co., Ltd. is increasing its investment in the company. Between the two deals, Ballard will receive an influx of cash totaling more than $180 million.

Top 10 Warren Buffett Stocks For 2019: (LGF.A)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ValuEngine cut shares of Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) from a sell rating to a strong sell rating in a research report released on Wednesday.

  • [By Stephan Byrd]

    Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) had its price target decreased by analysts at Barrington Research to $27.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has an “outperform” rating on the stock. Barrington Research’s price objective suggests a potential upside of 17.60% from the stock’s previous close.

  • [By Logan Wallace]

    ValuEngine upgraded shares of Lions Gate Entertainment Corp. Class A (NYSE:LGF.A) from a strong sell rating to a sell rating in a research note published on Thursday morning.

Top 10 Warren Buffett Stocks For 2019: Washington Federal, Inc.(WAFD)

Advisors’ Opinion:

  • [By Logan Wallace]

    Principal Financial Group Inc. boosted its stake in Washington Federal (NASDAQ:WAFD) by 12.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,301,596 shares of the bank’s stock after buying an additional 142,766 shares during the period. Principal Financial Group Inc. owned approximately 1.54% of Washington Federal worth $45,035,000 as of its most recent filing with the SEC.

  • [By Ethan Ryder]

    Washington Federal Inc. (NASDAQ:WAFD) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $30.66 and last traded at $32.15, with a volume of 5270 shares changing hands. The stock had previously closed at $31.85.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Washington Federal (WAFD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Bank of New York Mellon Corp decreased its stake in shares of Washington Federal Inc. (NASDAQ:WAFD) by 2.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,171,861 shares of the bank’s stock after selling 25,224 shares during the quarter. Bank of New York Mellon Corp’s holdings in Washington Federal were worth $38,320,000 at the end of the most recent reporting period.

Top 10 Warren Buffett Stocks For 2019: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By Cory Renauer]

    This is an exciting time to own shares of Galapagos NV (NASDAQ:GLPG), TG Therapeutics Inc. (NASDAQ:TGTX), or Mirati Therapeutics Inc. (NASDAQ:MRTX). All three of these biotechs are presenting clinical trial results that could send their stock prices soaring, or sinking, in the weeks ahead.

  • [By Cory Renauer]

    This year’s biggest oncology conference delivered some surprises and gave investors plenty to look forward to in the months ahead. Loxo Oncology Inc. (NASDAQ:LOXO), and TG Therapeutics (NASDAQ:TGTX) are already having a great year that could get a lot better, while recently beaten down Nektar Therapeutics (NASDAQ:NKTR) will get a chance to redeem itself.

  • [By Shane Hupp]

    TG Therapeutics Inc (NASDAQ:TGTX)’s share price traded down 3.2% during mid-day trading on Tuesday . The stock traded as low as $9.30 and last traded at $9.10. 56,980 shares were traded during mid-day trading, a decline of 94% from the average session volume of 962,658 shares. The stock had previously closed at $9.40.

  • [By Paul Ausick]

    TG Therapeutics Inc. (NASDAQ: TGTX) dropped about 40% Tuesday to set a new 52-week low of $5.50. Shares closed at $9.25 on Monday and the stock’s 52-week high is $17.35. Volume was about 70% higher than the daily average of around 7.4 million. The company said it is no longer considering an accelerated application for a clinical drug trial.

  • [By George Budwell]

    Shares of the B-cell malignancy and autoimmune disease specialist TG Therapeutics (NASDAQ:TGTX) fell by an eye-popping 55.9% last month, according to data from S&P Global Market Intelligence. What triggered this dramatic sell-off?

Top 10 Warren Buffett Stocks For 2019: ClearSign Combustion Corporation(CLIR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Press coverage about Clearsign Combustion (NASDAQ:CLIR) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clearsign Combustion earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the technology company an impact score of 46.3610235421976 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

  • [By Stephan Byrd]

    Headlines about Clearsign Combustion (NASDAQ:CLIR) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clearsign Combustion earned a news impact score of 0.03 on Accern’s scale. Accern also assigned media stories about the technology company an impact score of 46.3826189369742 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Top 10 Warren Buffett Stocks For 2019: Visteon Corporation(VC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Investors bought shares of Visteon Corp (NYSE:VC) on weakness during trading hours on Friday. $25.19 million flowed into the stock on the tick-up and $13.69 million flowed out of the stock on the tick-down, for a money net flow of $11.50 million into the stock. Of all companies tracked, Visteon had the 19th highest net in-flow for the day. Visteon traded down ($2.64) for the day and closed at $112.62

  • [By Shane Hupp]

    Visteon Corp (NYSE:VC) – Equities research analysts at B. Riley increased their FY2019 earnings per share estimates for shares of Visteon in a report issued on Tuesday, October 2nd. B. Riley analyst C. Horn now expects that the auto parts company will earn $6.83 per share for the year, up from their previous estimate of $6.00.

  • [By Stephan Byrd]

    VirtualCoin (CURRENCY:VC) traded flat against the US dollar during the twenty-four hour period ending at 16:00 PM ET on June 19th. One VirtualCoin coin can currently be purchased for approximately $0.0119 or 0.00000144 BTC on exchanges. During the last seven days, VirtualCoin has traded 33.1% lower against the US dollar. VirtualCoin has a market cap of $120,251.00 and approximately $0.00 worth of VirtualCoin was traded on exchanges in the last 24 hours.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Visteon (VC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    VirtualCoin (CURRENCY:VC) traded flat against the dollar during the 24 hour period ending at 19:00 PM E.T. on August 14th. One VirtualCoin coin can now be bought for $0.0119 or 0.00000144 BTC on popular cryptocurrency exchanges. VirtualCoin has a market cap of $120,251.00 and approximately $0.00 worth of VirtualCoin was traded on exchanges in the last day. During the last seven days, VirtualCoin has traded down 33.1% against the dollar.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Visteon (VC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Warren Buffett Stocks For 2019: Ishares Trust Dj Us Financial (IYF)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    The challenges facing EUFN may indicate the ETF will be challenged to deliver compelling risk-reward for investors. EUFN's three-year standard deviation is 18.23 percent, or more than 500 basis points above the same metric on the iShares U.S. Financials ETF (NYSE: IYF).

Top 10 Warren Buffett Stocks For 2019: Saia Inc.(SAIA)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saia (SAIA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Verition Fund Management LLC bought a new stake in Saia Inc (NASDAQ:SAIA) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,872 shares of the transportation company’s stock, valued at approximately $441,000.

  • [By Max Byerly]

    State of Tennessee Treasury Department trimmed its holdings in Saia Inc (NASDAQ:SAIA) by 9.5% during the first quarter, HoldingsChannel.com reports. The fund owned 17,868 shares of the transportation company’s stock after selling 1,877 shares during the period. State of Tennessee Treasury Department’s holdings in Saia were worth $1,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Top 10 Warren Buffett Stocks For 2019: Carriage Services, Inc.(CSV)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Carriage Services (CSV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Carriage Services (CSV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    DF Dent & Co. Inc. reduced its stake in shares of Carriage Services, Inc. (NYSE:CSV) by 12.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,243 shares of the company’s stock after selling 14,353 shares during the quarter. DF Dent & Co. Inc.’s holdings in Carriage Services were worth $2,486,000 at the end of the most recent quarter.

Top 10 Warren Buffett Stocks For 2019: NorthStar Realty Europe Corp.(NRE)

Advisors’ Opinion:

  • [By Stephan Byrd]

    NorthStar Realty Europe (NYSE:NRE) has been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.17.

  • [By Joseph Griffin]

    Pebblebrook Hotel Trust (NYSE: NRE) and Northstar Realty Europe (NYSE:NRE) are both finance companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

  • [By Joseph Griffin]

    Northstar Realty Europe Corp (NYSE:NRE) has earned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.83.

  • [By Shane Hupp]

    Teachers Insurance & Annuity Association of America increased its holdings in NorthStar Realty Europe (NYSE:NRE) by 15.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,499 shares of the financial services provider’s stock after purchasing an additional 9,699 shares during the period. Teachers Insurance & Annuity Association of America owned approximately 0.13% of NorthStar Realty Europe worth $931,000 as of its most recent SEC filing.

  • [By Jim Royal]

    Investors in NorthStar Realty Europe (NYSE:NRE) woke up to news Tuesday morning that one of the company’s largest investors is looking to shake things up at the company. Senvest Management, which owns 9.55% of NorthStar, is pushing the company’s external advisor, Colony Capital (NYSE:CLNY), to realize value at the undervalued European REIT, after years of a stagnating stock price.

good stocks to buy today

Coca-Cola (NYSE:KO) is a dividend growth machine that I started covering last fall with a buy rating, especially if you could get shares for under $40. I have said of course that shares appeared that would be tough to acquire under $40 but that chance has arrived. It finally happened. The stock has been a tough investment lately as it has been a name that has moved sideways to down here in 2016. But for those seeking a safe investment for income, Coca-Cola has to be on the list and the yield is now hitting 3.5%. Remember that when I started coverage I stated that Coca-Cola was a name that “you buy for income/dividend growth. Capital appreciation is secondary.” And friends, Coca-Cola is a sparkling example of a dividend growth name. I continue to think that the stock is best served in a long-term, tax deferred account like an IRA, with the ultimate goal of reinvesting the dividends and amassing a large position. But is this stock worth holding?

The short answer is yes, but I would go so far as to say this stock is approaching a real buying opportunity. I said under $40 I liked it. That hasn’t changed. But as the stock continues to fall, let it. Buy incrementally. Now, long-term is the buy worth it? For the long answer to this question I will examine the recently reported results and discuss the outlook for the stock. Let me start with some highlights. First the company saw revenue of $10.63 billion which beat analyst expectations by $9 million, but it was also down 7.0% year-over-year. Ouch. Earnings continue to be strong, with Q3earnings coming in at $0.49, which was a $0.01 beat against estimates.

good stocks to buy today: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto

good stocks to buy today: Packaging Corporation of America(PKG)

Advisors’ Opinion:

  • [By Christopher Freeburn]

    Shares of Packaging Corp. (PKG) jumped almost 13% in pre-market trading on Monday after the company announced that it will purchase a rival containerboard-maker.

  • [By Daniela Pylypczak]

    Jefferies announced on Monday that it has upgraded Packaging Corp of America (PKG) from “Hold” to “Buy.”

    The firm also raised PKG’s price target from $49.00 to $70.00. Jefferies analystPhilip Ng also gave the companybull-case scenario target of $88. The upgrade comes after the firm announced earlier today that it has agreed to purchase all outstanding shares of Boise Inc. (BZ)for $1.995 billion. Analyst Ng believes the new acquisition will result in an attractive multiple.

    Packaging Corp of America shares rallied 9.73% during Monday’s session. Year-to-date, the stock is up 39.87%.

  • [By Ben Levisohn]

    Packaging Corp. of America(PKG) has jumped 6.3% to $57.99 after it said it would buy Boise (BZ) for $1.28 billion. Boise has gained 26% to $12.55.

  • [By Paul Ausick]

    Stocks on the move: Boise Inc. (NYSE: BZ) is up 26% at $12.55 following the companys acquisition by Packaging Corporation of America Inc. (NYSE: PKG) for $12.55 a share ($1.28 billion). Omeros Corp. (NASDAQ: OMER) is up 68.2% at $8.56 following an analyst upgrade. Northern Dynasty Minerals Ltd. (NYSEArca: NAK) is down 33.3% at $1.48 following an announcement from Anglo American plc that it was withdrawing from a massive copper mining project in Alaska.

good stocks to buy today: Air Industries Group(AIRI)

Advisors’ Opinion:

  • [By Dividends4Life]

    Air Industries Group Inc. (AIRI), an aerospace and defense company, designs and manufactures structural parts and assemblies that focus on flight safety. Sept. 17, the company increased its quarterly dividend 100% to $0.125 per share. The dividend is is payable Oct. 15, 2013 to shareholders of record as of the close of business on Sept. 30, 2013. The yield based on the new payout is 6.9%.

good stocks to buy today: TrovaGene, Inc.(TROV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of TrovaGene Inc (NASDAQ: TROV) were down 13 percent to $5.28. Trovagene reported a Q4 loss of $(0.26) per share.

    Sunrun Inc (NASDAQ: RUN) was down, falling around 13 percent to $6.22. Sunrun reported a Q4 loss of $(0.15) per share on revenue of $99.6 million.

  • [By Lisa Levin]

    TrovaGene Inc (NASDAQ: TROV) was down, falling around 42 percent to $0.25. Trovagene priced its 15 million share common stock offering at $0.30 per share.

  • [By Lisa Levin]

    TrovaGene Inc (NASDAQ: TROV) shares dropped 27 percent to $1.27. Trovagene reported a Q4 loss of $8.5 million on revenue of $68,000. Piper Jaffray downgraded TrovaGene from Neutral to Underweight.

  • [By Paul Ausick]

    TrovaGene Inc. (NASDAQ: TROV) dropped about 44% Friday to post a new 52-week low of $0.24 after closing at $0.43 on Thursday. Volume was around 12.5 million, about 20 times the daily average of around 650,000. The firm this morning priced an offering of 15 million shares and warrants to purchase up to another 15 million shares at $0.30 per unit.

  • [By Lisa Levin]

    TrovaGene Inc (NASDAQ: TROV) was down, falling around 40 percent to $0.26. Trovagene priced its 15 million share common stock offering at $0.30 per share.

good stocks to buy today: Strayer Education, Inc.(STRA)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, non-cyclical consumer goods & services shares fell by 1.21 percent. Meanwhile, top losers in the sector included Strayer Education Inc (NASDAQ: STRA), down 13 percent, and MGP Ingredients Inc (NASDAQ: MGPI), down 6 percent.

  • [By Lisa Levin]

    Shares of Capella Education Company (NASDAQ: CPLA) got a boost, shooting up 32 percent to $86.60. Strayer Education Inc (NASDAQ: STRA) and Capella Education agreed to an all-stock merger. Capella Education also posted upbeat quarterly earnings.

Top 10 Undervalued Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top 10 Undervalued Stocks To Invest In Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Peter Graham]

    Headquartered in New York City, large cap L3 Technologies Inc (NYSE: LLL) employs approximately 38,000 people worldwide and is a leading provider of a broad range of communication, electronic and sensor systems used on military, homeland security and commercial platforms. L3 is also a prime contractor in aerospace systems, security and detection systems, and pilot training. The Company reported 2016 sales of $10.5 billion.

Top 10 Undervalued Stocks To Invest In Right Now: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By WWW.THESTREET.COM]

    “There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.

  • [By Peter Graham]

    On the earnings call, Ellison noted that the company had surpassed Salesforce.com, inc (NYSE: CRM) in annualized recurring cloud revenue: We are now well on our way to passing them and becoming number one in the enterprise SaaS market.”

Top 10 Undervalued Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

Top 10 Undervalued Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top 10 Undervalued Stocks To Invest In Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

Top 10 Undervalued Stocks To Invest In Right Now: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Undervalued Stocks To Invest In Right Now: Cemex S.A.B. de C.V.(CX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cemex SAB de CV (CX) is very interesting at these levels as it seems the market is pricing in a stronger dollar (thereby reducing revenue) and thus lower growth.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.4% Friday to post a new 52-week low of $7.41 after closing at $7.59 on Thursday. The 52-week high is $10.37. Volume was around 8.8 million, about 15% below the daily average of around 9.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.7% Thursday to post a new 52-week low of $7.57 after closing at $7.78 on Wednesday. The 52-week high is $10.37. Volume was around 6.8 million, about 15% below the daily average of around 8.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 1.8% Wednesday to post a new 52-week low of $7.16 after closing at $7.29 on Tuesday. The 52-week high is $10.37. Volume was around 7 million, about 20% below the daily average of around 9.5. The Mexico-based cement company had no specific news.

Top 10 Undervalued Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

Top 10 Undervalued Stocks To Invest In Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Undervalued Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Top 5 Heal Care Stocks To Invest In Right Now

Megyn Kelly was arguably the highest-profile media figure of the 2016 campaign, thanks to her exchanges with Donald Trump. Yet as Trump was sworn in as president, the former Fox News anchor stayed sidelined, waiting to start her new assignment at NBC News.

Set up to host two different shows — including an hour of “Today” come fall — “Sunday Night With Megyn Kelly” marked her official NBC debut, armed with a high-profile “get” interview with Russian leader Vladimir Putin.

In a CNN interview, Kelly maintained “Sunday Night” would distinguish itself by being “cutting edge” and “a little irreverent.” Those attributes, however, weren’t particularly evident in a premiere that looked like pretty much any conventional newsmagazine, including separate pieces from Cynthia McFadden and Harry Smith.

Kelly’s centerpiece interview displayed some of the toughness that defined her at Fox, expressing disbelief when the Russian president claimed he hadn’t spoken with his ambassador about meetings with Trump’s inner circle. “Never?” she asked, with an arched eyebrow.

Top 5 Heal Care Stocks To Invest In Right Now: Helios and Matheson Analytics Inc(HMNY)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Helios and Matheson Analytics Inc. (Nasdaq: HMNY) is an information technology company that provides its clients predictive analytics. The company uses big data for most of its software and operates within the financial services, insurance, and healthcare industries. HMNY is up 278% YTD after it announced a strategic merger with a GPS application company, called RedZone Maps. RedZone is known for mapping crime in major cities. News of the merger sent HMNY climbing over 1,000% from $1.11 per share to $13.75 per share over the course of a week. The stock has since fallen to $5.23 per share as of Monday intraday.

  • [By Lisa Levin]

    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares dropped 32 percent to $6.87 after the company reported a common stock offering. The size of the offering was not disclosed. The company said that proceeds from the offering and warrants will be used to increase the company’s ownership stake in MoviePass.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto

Top 5 Heal Care Stocks To Invest In Right Now: International Business Machines Corporation(IBM)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    The role of International Business Machines Corp.(NYSE: IBM) CEO Ginni Rometty as an advisor to President Trump has caused deep concern among some of her employees. She may find out the hard way that the problem could spread to shareholders and customers, as it has to those at other companies.

  • [By Money Morning Staff Reports]

    A nearly 9% rally on Oct. 18 gave International Business Machines Corp. (NYSE: IBM) shareholders a long-awaited reprieve from the bear market that was 2017. It was the stock’s single best day in nine years.

  • [By Danny Vena]

    IBM (NYSE:IBM) is rolling out a new weapon in cyberdefense: its Jeopardy!-winning cognitive supercomputer Watson. So how will a game show contestant help prevent hacking? Glad you asked, but first, a little background.

Top 5 Heal Care Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

Top 5 Heal Care Stocks To Invest In Right Now: Annaly Capital Management Inc(NLY)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Another tax-law provision gives favorable tax status to real-estate investment trusts. REITs make investments in real estate-related assets, and they’re required to pay out almost all their income to their shareholders annually.
    Simon Property Group (SPG) is one of the biggest REITs, focusing on shopping malls and paying a 3 percent yield. But other specialty areas of the REIT universe pay much higher dividends, with REITs like Annaly Capital (NLY) that invest in mortgage-backed securities topping the list with double-digit percentage yields.

  • [By Amanda Alix]

    It was just about one year ago that QE3 made its debut, and mortgage REITs, particularly agency-only players like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) began moaning about the increased competition for mortgage-backed securities guaranteed by Fannie Mae and Freddie Mac.

  • [By Boniface Murigu]

    It’s no secret that mREITs such as American Capital Agency (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) , Annaly Capital Management (NYSE: NLY  ) (NYSE: NLY  ) (NYSE: NLY  ) ,and CYS Investmentshave gone through a very turbulent trading period, with all major players losing a sizable share of market value.

  • [By Amanda Alix]

    This development will likely give battered mREITs like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) a huge boost as investors begin to feel less panic regarding a tapering of the current QE3 program. Markets have responded to the Summers announcement by soaring skyward, apparently feeling relief and confidence about the fate of the taper.

  • [By Ben Levisohn]

    Hatteras Financial (HTS) has jumped 9.4% to $15.60 after agreeing to be purchased byAnnaly Capital Management (NLY) for $1.5 billion.Annaly Capital Management has dropped 1.1% to $$10.30.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

Top 5 Heal Care Stocks To Invest In Right Now: Safe Bulkers Inc(SB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    StarBulk Carriers (SBLK) and Safe Bulkers (SB) have more than tripled during the past 12 months, while Golden Ocean Group (GOGL) has more than doubled. So it must be time for an upgrade right?

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.